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Abstract
Introduction: Bronchial anthracofibrosis (BAF), confirmed bronchoscopically, is characterised by bluish-black mucosal pigmenta-
tion and distortion/narrowing of the bronchus. We investigated the occurrence of BAF in respiratory symptomatics with biomass 
fuel smoke exposure and evaluated its clinico-radiological attributes and impact on functional status. 
Material and methods: Of the eighty subjects evaluated, 60 consented for fiberoptic bronchoscopy (FOB). All 60 subjects also 
underwent chest radiography, high resolution computed tomography (HRCT) of the thorax, spirometry with reversibility testing 
and six-minute-walk test. Information regarding cardinal respiratory symptoms and duration of biomass fuel smoke exposure 
was documented. FOB evaluation revealed that 24 patients had BAF (Group 1), 17 had bronchial anthracosis (Group 2) and 19 
had normal appearance (Group 3). 
Results: Group 1 patients had significantly higher biomass fuel smoke exposure (p < 0.0001) and lower walk distance (p = 0.003) 
with greater desaturation. On HRCT, segmental collapse and consolidation were significantly higher in Group 1 while fibrotic 
lesions were the predominantly seen in Groups 2 and 3. A significant inverse correlation in Group 1 was seen between expo-
sure index, six-minute-walk distance and spirometric parameters. In Group 1, the right middle lobe (RML) bronchus was most 
commonly involved (15/24 [62.5%]). In Group 2, RML and left upper lobe bronchi were affected in 8/17 (47.1%) patients each. 
Conclusions: All patients in our study were females. Those with BAF had poorer functional status as compared to those with 
anthracosis only. On imaging, multifocal bronchial narrowing was specific to BAF.
Key words: anthracosis; biomass fuel smoke; bronchial anthracofibrosis; fiberoptic bronchoscopy; high resolution computed 
tomography of the thorax
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Introduction
Pearson [1] coined the term “Anthracosis” in 
1813 to highlight the bluish-black discolouration 
of the bronchial mucosa caused by inhalation of 
soot. This phenomenon was frequently seen in 
coal workers, cigarette smokers and city dwellers. 
Endobronchial pigmentation with airway nar-
rowing was first described in 1951 by Abraham 
Cohen [2] when he described middle lobe narro-
wing in eight female patients due to perforated 
tuberculous lymph nodes. Six of these eight 
patients had anthracotic pigmentation in the ri-
ght middle lobe. This would seem to be the first 
ever description of “bronchial anthracofibrosis 
(BAF)”, a  term first coined by Chung et al. [3] 
from Korea. They described bronchoscopically 
visible anthracotic pigmentation with narrowing/
distortion of the bronchi in 20/28 elderly subjects 
with significant wood smoke exposure. They por-
trayed the clinical peculiarity of the disease and 
highlighted that the right middle lobe was most 
commonly involved and was associated with ac-
tive tuberculosis in 61%. The authors even favo-
ured expeditious initiation of anti-tuberculous 
therapy as they postulated that BAF was caused 
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by “fibrotic response to active or old tuberculous 
infection”. However, a mounting body of evidence 
has emerged to impute long standing biomass fuel 
smoke exposure as major incriminating factor [4].
It is currently estimated that nearly half the 
world’s population, especially in the developing 
countries, is dependent on biomass fuel such as 
wood, charcoal, animal dung for cooking and 
heating their homes [5]. Indoor combustion of 
biomass solid fuels has been identified by the 
World Health Organization as the fourth leading 
risk factor for disease burden worldwide [6]. In-
complete combustion of these fuels is the source of 
smoke containing approximately 200 compounds 
of gaseous pollutants along with solid particulate 
matter. Cooking is frequently done in poorly venti-
lated areas with kitchen being combined with the 
living area. Blackish soot deposition is frequently 
seen lining the ceilings and walls in these areas [4].
BAF was first reported from India in a 65-year
-old female with longstanding history of wood 
smoke exposure who presented with a middle 
lobe syndrome (MLS) [7]. Fibrebronchoscopy 
confirmed the presence of anthracotic pigmen-
tation with narrowing of the right middle lobe 
bronchus and Mycobacterium tuberculosis was 
cultured from bronchial aspirate. With increasing 
awareness of BAF in our country, we attempted to 
ascertain the occurrence of BAF and anthracosis 
in respiratory symptomatics with long standing 
history of biomass fuel smoke exposure. In ad-
dition, the study endeavours to determine the 
clinical, spirometric, imaging and bronchoscopic 
characteristics of BAF and anthracosis. 
Material and methods
Study population 
Newly referred respiratory symptomatics, 
40 years and above, with history of exposure to 
biomass fuel smoke were recruited sequentially. 
Patients were never smokers, stable and ambula-
tory on inclusion and excluded if they had com-
plications or significant comorbidities.
 Study design
This was an institute based prospective ob-
servational study. All patients responded to a qu-
estionnaire seeking information about cardinal 
respiratory symptoms and was filled in by the same 
investigator. Detailed history of biomass fuel smo-
ke exposure in terms of exposure index (average 
number of hours of exposure per day multiplied by 
the number of years of cooking) [8] and ventilation 
were also recorded. All patients underwent spiro-
metry with reversibility testing, chest radiograph 
and high resolution computed tomography (HRCT) 
of the thorax. Spirometric findings were classified 
as normal and abnormal. The abnormal pattern was 
further divided into obstructive and non-obstructi-
ve defect. Obstructive ventilatory impairment was 
defined as post-bronchodilator FEV1/FVC < lower 
limit of normal (LLN) while the non-obstructive 
ventilatory impairment comprised patterns sugge-
stive of restriction or mixed ventilatory defect [9]. 
All HRCT images were analysed independently 
by a pulmonologist and a radiologist, both with 
more than 30 years of experience. The diagnostic 
criteria adopted for BAF [4, 10] were: (1) long-stan-
ding history of biomass fuel smoke exposure, (2) 
on HRCT, the occurrence of multifocal narrowing 
of involved bronchus when present and (3) visual 
confirmation on fibreoptic bronchoscopy (FOB) of 
(a) bluish-black mucosal pigmentation, along with 
(b) narrowed/distorted bronchus. FOB was done 
only in those who gave a written informed consent 
again prior to the procedure.
Grouping of study subjects
Based on the FOB findings, the study popu-
lation was divided into three groups: Group 1: 
patients with anthracotic pigmentation and nar-
rowed/distorted bronchi (BAF), (Fig. 1A) Group 
2: patients with only anthracotic pigmentation 
without narrowing/distortion (Fig. 1B) and Group 
3: patients with a normal tracheobronchial tree.
Ethics 
Patients were recruited if they gave a volun-
tary, informed and written consent. Subsequently, 
written consent for FOB was also taken prior to 
conducting the procedure. The study was appro-
ved by the institutional Human Ethics Committee.
Statistical analysis
Data are reported as mean ± SD or number 
(%). Analysis was performed using Statistical 
Package for the Social Sciences Version 21.0 
(IBM Corporation, Armonk, NY, USA). The nor-
malcy of distribution was assessed using the 
Shapiro-Wilk test while Levene test was used to 
determine homogeneity of variance. The data was 
normally distributed in all the three groups and 
thus the groups were compared using ANOVA 
test for continuous variables and the chi-square 
test for categorical variables. Post-hoc analysis 
was performed using the Tukey’s post hoc test. In 
addition, Pearson’s correlation coefficient was to 
determine correlation between variables. P-value 
of < 0.05 was considered statistically significant.
Vikas Pilaniya et al., Occurrence of bronchial anthracofibrosis
129www.journals.viamedica.pl
A B
Figure 1. A — fiberoptic bronchoscopy image showing anthracotic pigmentation along with narrowing/distortion of the right middle lobe bronchus 
confirmatory of bronchial anthracofibrosis; B — fiberoptic bronchoscopy image showing anthracotic patch in the wall of right upper lobe bronchus
Results
Eighty consecutive respiratory symptoma-
tics, all females, never smokers with biomass 
fuel smoke exposure were enrolled but 20 were 
excluded as they refused FOB. The remaining 
60 patients (mean age of 58.3 ± 9.96 years) were 
categorised after FOB as Group 1: BAF 24/60 
(40%), Group 2: bronchial anthracosis 17/60 
(28.3%) patients and Group 3: normal appearan-
ce: 19/60 (31.7%). Though Group 1 patients had 
significantly higher mean age (Table 1), there 
was no significant differences in presentation 
of three groups (Table 2). There was a  signi-
Table 1. Age and biomass fuel smoke exposure among the three groups
BAF (n = 24)
Group 1
Anthracosis 
(n = 17)
Group 2
Normal bron-
choscopy  
(n = 19)
Group 3
p-value
(ANOVA)
Post-hoc analysis
between the groups
(Tukey’s post hoc test)
Mean age in years 61.5 ± 11.5 57.6 ± 8.1 54.9 ± 8.4 0.049* Group 1 vs  Group 2 : 0.42
Group 1 vs  Group  3 : 0.04*
Group 2 vs  Group 3 : 0.69
Mean hours of exposure/day 5.75 ± 0.85 4.53 ± 0.51 4.89 ± 0.87 < 0 .001* Group 1 vs  Group 2 : 0.0001*
Group 1 vs  Group 3 : 0.0001*
Group 2 vs  Group 3 : 0.004*
Mean years of exposure 32.3 ± 9.9 27.94 ± 9.7 21.3 ± 4.9 < 0.001* Group 1 vs  Group 2 : 0.0001*
Group 1 vs  Group 3 : 0.0001*
Group 2 vs  Group 3 : 0.984
Mean exposure index 181.5 ± 50.6 127.9 ± 44.2 106.3 ± 24.6 < 0.0001* Group 1 vs  Group 2 : 0.0001*
Group 1 vs  Group 3 : 0.0001*
Group 2 vs  Group 3 : 0.275
*statistically significant
Table 2. Clinical symptomatology in the three groups
BAF (n = 24)
Group 1
Anthracosis (n = 17)
Group 2
Normal bronchoscopy (n = 19)
Group 3
p-value
Cough 23 (95.83%) 16 (94.12%) 19 (100%) 0.59
Dyspnoea 19 (79.17%) 15 (88.24%) 19 (100%) 0.10
Sputum 11 (45.83%) 4 (23.53%) 6 (31.58%) 0.31
Chest pain 4 (16.67%) 4 (23.53%) 2 (10.53%) 0.57
Haemoptysis 7 (29.17%) 1 (5.88%) 3 (15.79%) 0.15
Wheeze 7 (29.17%) 5 (29.41%) 5 (26.32%) 0.97
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Figure 2. Box and whisker plot showing the biomass fuel smoke 
exposure index in all three groups
ficant difference in the mean exposure index 
between the three groups (p = 0.0001). Patients 
in Group 1 had significantly higher exposure 
index (Fig. 2) as compared to the other two gro-
ups (Group 1 vs Group 2: p = 0.0001; Group 1 
vs Group 3: p = 0.0001; Group 2 vs Group 3: 
p = 0.27) (Table 1).
Pulmonary function testing (PFT)
Spirometry was performed in 52/60 patients. 
In 7/24 Group 1 patients, the procedure was not 
performed as four had recent haemoptysis while 
another three could not perform the manoeuvre 
as also one patient from Group 2. 
An analysis of the spirometric findings in our 
study revealed that a majority of patients in all the 
three groups had an abnormal spirometry (Group 1: 
11/17 [64.7%], Group 2: 9/16 [56.3%] and Group 3: 
16/19 [84.2%]; p = 0.18). On spirometry, the most 
common ventilatory defect was a non-obstructive 
pattern (Group 1: 8/17 [47.1%] vs Group 2: 9/16 
[56.3%] vs Group3: 12/19 [63.2%]; p = 0.62). An ob-
structive pattern was seen in (Group 1: 3/17 [17.6%] 
vs Group 2: 0/16 (0%) vs Group 3: 4/19 [21.1%]; p 
= 0.15). A normal spirometry was documented in 
(Group 1: 6/17 [35.5%] vs Group 2: 7/16 [43.7%] 
vs Group 3:3/19 [15.8%]; p = 0.18) patients. There 
was no significant difference in the spirometric 
parameters between the three groups (Table 3).
Six minute walk test (6MWT)
In Group 1, the mean 6MWT distance was 
235.4 ± 69.97 metres, in Group 2 331.8 ± 105.97 
metres and in Group 3 270 ± 91.7 metres. Patients 
in Group 1 walked significantly lesser distance as 
compared to Group 2 (p = 0.003) but there was no 
significant difference between Groups 1 and 3 (p = 
0.41) and Groups 2 and 3 (p = 0.09). In Group 1, 
significant desaturation (a fall in SpO2 ≥ 4% from the 
baseline) [11] was seen in 14/24 (58%) patients, in 
Group 2 6/17 (35.3%) and in Group 3 6/19 (31.6%). 
Chest radiograph 
All 24 Group 1 patients had an abnormal 
chest X-ray with consolidation in 8/24 (33.3%) pa-
tients and reticulonodular pattern in 7/24 (29.2%). 
Ill-defined opacities abutting right cardiac border 
suggestive of middle lobe sydrome (Fig. 3A, B) 
and linear shadows were observed 6/24 (25%) 
patients each, atelectasis in 2/24 (8.3%) and hilar 
lymphadenopathy in 1/24 (4.1%) subjects.
In Group 2, reticulonodular pattern was seen 
in 5/17 (29.4%) patients, linear shadows in 4/17 
(23.4%), consolidation, hilar lymphadenopathy 
and a normal study in 3/17 (17.6%) patients each. 
In Group 3, the chest radiograph was normal in 
8/19 (42.1%) patients, reticulonodular pattern in 
Table 3. Spirometry findings in the three groups
 Parameters BAF (n = 17)
Group 1
Anthracosis (n = 16)
Group 2
Normal bronchoscopy
(n = 19)
Group 3
p-value
(ANOVA)
Post-hoc analysis
between the groups
(Tukey’s post hoc test)
 Mean  ±  SD Mean  ±  SD Mean  ±  SD
FEV1 67.1 ± 18.3% 63.4 ± 20.4% 53.8 ± 20.3% 0.12  Group 1 vs Group 2: 0.86
 Group 1 vs Group 3: 0.12
 Group 2 vs Group 3 : 0.32
FVC 79.4 ± 13.3% 68.8 ± 16.3% 69.7 ± 15.5% 0.08  Group 1 vs Group 2: 0.12
 Group 1 vs Group 3: 0.14
 Group 2 vs Group 3: 0.98
FEV1/FVC 69.8 ± 10.4% 75 ± 12.9% 64.2 ± 14.9% 0.06  Group 1 vs Group 2: 0.48
 Group 1 vs Group 3: 0.41
 Group 2 vs Group 3: 0.05
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Figure 3. A — chest X-ray postero-anterior view showing ill-defined opacity in the right mid and lower zones abutting the right cardiac border with loss 
of cardiac silhouette suggestive of right middle lobe syndrome; B — chest X-ray right lateral view showing a wedge-shaped density extending from 
the hilum anteriorly and inferiorly towards the chest wall, confirming the presence of middle lobe syndrome; C —  high-resolution CT of the thorax (lung 
window) showing a trapezoidal opacity with its base towards the hilum and contiguous with the right cardiac border confirming middle lobe syndrome
4/19 (21.1%), linear shadows and consolidation 
in 3/19 (15.8%) subjects each. 
HRCT thorax
In Group 1, segmental collapse and consoli-
dation were seen in 13/24 (54.2%) patients each, 
fibrotic lesions in 11/24 (45.8%), bronchial narro-
wing in 7/24 (29.3 %), middle lobe syndrome (Fig. 
3C) in 6/24 patients (25%), multifocal bronchial 
stenosis and peribronchial cuffing in 5/24 (20.8%) 
patients each. Mediastinal lymphadenopathy was 
reported in 5/24 (20.8%) patients, emphysema 
in 4/24 (16.7%), traction bronchiectasis in 3/24 
(12.5%) and interstitial pattern in one. In Group 2, 
parenchymal bands was documented in 14/17 
(82.4%) patients, traction bronchiectasis in 6/17 
(35.3%), ground glass opacity and mediastinal 
lymphadenopathy in 4/17 (23.5%) subjects each. 
In Group 3 patients, parenchymal bands was seen 
in 11/19 (57.9%) patients, traction bronchiectasis 
and emphysema in 5/19 (26.3%) subjects each.
Multifocal bronchial stenosis (Fig. 4) and 
peribronchial cuffing was seen in 5 patients each 
while tree in bud appearance and usual inter-
stitial pneumonia in one patient each. All these 
findings were documented exclusively in patients 
with BAF (Table 4).
Bronchoscopy findings
In both groups, the middle lobe bronchus was 
most commonly affected in 23/41 subjects (Group 
1: 15/24 [62.5%] vs Group 2: 8/17 [47.1%]; [p = 
0.32]). This was followed by the right upper lobe 
bronchus in 17/41 patients of both groups (Group 
1:10/24 [41.7%] vs Group 2: 7/17 [41.2%]; [p = 
0.97]). The left upper lobe bronchus was involved 
in 15/41 patients (Group 1: 7/24 [29.2%] versus 
Group 2: 8/17 [47.1%]; [p = 0.24]) while the left 
lower lobe bronchus was affected exclusively in 
4 patients with anthracosis (Group 2) (Group 1: 
0/24 vs Group 2 4/17 [23.5%]; [p = 0.01]).
Other associated pulmonary diseases
Tuberculosis was reported in 4/60 (6.6%) pa-
tients. In Group 1, a positive microbiological and 
histopathological evidence for Mycobacterium 
tuberculosis was observed in 3/24 (12.5%) patients 
while one patient in Group 3 had associated 
tuberculosis. Adenocarcinoma and pneumonia 
were associated findings in 2/24 (8.3%) patients 
while one patient had interstitial lung disease 
(usual interstitial pneumonia pattern [UIP]) asso-
ciated with BAF. Adenocarcinoma was associated 
in one Group 2 patient. Associated COPD was 
seen in 8/24 (33.33%) patients in Group 1, 5/17 
(29.41%) patients in Group 2 and 14/19 (73.68%) 
in Group 3. 
Figure 4. High resolution computed tomography of the thorax (lung 
window) showing multifocal narrowing of the left upper lobe bronchus 
(white arrows)
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Table 4. Comparison of HRCT chest findings between patients with BAF, anthracosis and normal bronchoscopy
HRCT findings BAF
(n = 24)
Anthracosis 
(n = 17)
Normal bronchoscopy  
(n = 19)
p-value
Freq. % Freq. % Freq. %
Parenchymal bands 11 45.8 14 82.4 11 57.9 0.06
Segmental collapse 13 54.2 3 17.6 1 5.3 0.001*
Consolidation 13 54.2 3 17.6 1 5.3 0.001*
Bronchial narrowing 7 29.2 0 0.0 3 15.8 0.04*
Middle lobe syndrome 6 25 0 0 0 0 0.006*
 Multifocal bronchial stenosis 5 20.8 0 0.0 0 0.0 0.01*
 Peribronchial cuffing 5 20.8 0 0.0 0 0.0 0.01*
Emphysema 4 16.7 1 5.9 5 26.3 0.25
Mediastinal lymph nodes 5 20.8 4 23.5 2 10.5 0.55
Traction bronchiectasis 3 12.5 6 35.3 5 26.3 0.21
Mosaic pattern 5 20.8 3 17.6 2 10.5 0.82
Ground glass opacification 3 12.5 4 23.5 4 21.1 0.62
Tree in Bud 1 4.2 0 0.0 0 0.0 0.46
Cavitary lesion 3 12.5 0 0.0 2 10.5 0.33
 Interstitial pattern 1 4.2 0 0.0 0 0.0 0.46
No abnormal finding 0 0.0 0 0.0 0 0.0
*Statistically significant
Correlation
In Group 1 patients, the exposure index had 
significantly inverse correlation with six minute 
walk distance (r = –0.53; p = 0.008). In addition, 
exposure index also had a  significant inverse 
correlation with spirometric parameters (FVC: 
r = –0.50, p = 0.04; FEV1: r = –0.51, p = 0.03; 
FEV1/FVC: r = –0.48, p = 0.04) signifying worse 
lung functions with greater degree of exposure. 
In Groups 2 and 3, among the various parameters, 
only age had a  significant positive correlation 
with exposure index (Group 2: r = 0.55, p = 0.02; 
Group 3: r = 0.52, p = 0.02). In Group 1 patients, 
age had a positive correlation however this was 
not significant. This has been depicted in Table 5. 
Discussion
Our study has shown that BAF can occur in 
40% of respiratory symptomatics elderly females 
with biomass fuel smoke exposure. In addition, 
another 28.3% of the subjects had anthracosis. 
All our patients were females from rural back-
ground with long standing exposure to biomass 
fuel smoke while cooking in poorly ventilated 
areas. Since only never smokers were enrolled, 
male subjects with biomass fuel smoke exposure 
were smokers and had to be excluded. Gupta and 
Shah [10] in their review on BAF observed that 
632/792 (79.8%) patients with BAF were females. 
The mean exposure index in 42 non-smoking 
females with COPD from Brazil [12] was 209.1 
± 98.4 hour-years. A multivariate analysis from 
India [13] calculated that minimum threshold of 
exposure index of 60 hour-years was a significant 
risk factor for occurrence of chronic bronchitis in 
women. Our study too highlighted this aspect as 
mean years of exposure as well as mean exposure 
index was significantly higher in patients with 
BAF (BAF-181.5 ± 50.6 hour-years vs anthraco-
sis- 127.9 ± 44.2 hour-years). 
All patients with BAF had an abnormal radio-
logical study with consolidation and middle lobe 
collapse being the prominent finding on chest 
radiograph. On HRCT thorax, segmental collapse 
and consolidation were commonest observations 
along with parenchymal bands. Bronchial abnor-
malities in form of narrowing, multifocal bronchial 
stenosis, a feature indicative of BAF and peribron-
chial cuffing were observed. An unusual associa-
tion of BAF with UIP was observed which was do-
cumented in detail [14]. In two studies from Korea 
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Table 5. Correlation between variables in Groups 1, 2 and 3 
GROUP 1
Age Exposure index 6MWD FVC FEV1 FEV1/FVC
Age Pearson correlation 1 0.332 –0.135 0.232 0.307 0.077
Significance 0.113 0.528 0.37 0.23 0.76
Exposure index Pearson correlation 0.332 1 –0.528* –0.501* –0.514* -0.485*
Significance 0.113 0.008 0.040 0.035 0.048
6MWD Pearson correlation –0.135 –0.528** 1 0.749** 0.877* 0.789**
Significance 0.528 0.008 0.001 0.0001 0.0001
GROUP 2
Age Pearson correlation 1 0.559* –0.206 –0.074 0.120 0.206
Significance 0.02 0.427 0.786 0.659 0.443
Exposure index Pearson correlation 0.559* 1 –0.110 –0.204 –0.113 0.03
Significance 0.02 0.673 0.448 0.678 0.909
6MWD Pearson correlation –0.206 –0.110 1 –0.057 –0.154 –0.106
Significance 0.427 0.673 0.833 0.570 0.695
GROUP 3
Age Pearson correlation 1 0.529* –0.112 0.263 0.068 -0.086
Significance 0.02 0.647 0.277 0.781 0.726
Exposure index Pearson correlation 0.529* 1 –0.177 –0.160 –0.372 –0.387
Significance 0.02 0.469 0.512 0.117 0.101
6MWD Pearson correlation –0.112 –0.177 1 0.430 0.279 0.100
Significance 0.647 0.469 0.066 0.247 0.683
**Correlation is significant at the 0.01 level (2-tailed)
*Correlation is significant at the 0.05 level (2-tailed)
[15, 16] assessing CT features, bronchial narrowing/ 
/atelectasis was the most common finding. Of the 58 
patients with isolated BAF from Iran [17], peribron-
chial soft tissue thickening, bronchial narrowing 
or obstruction, segmental atelectasis, and lobar or 
multilobar collapse were the major findings. The 
CT findings in the two patients reported from India 
[7, 14] included a MLS with air bronchogram and 
multifocal stenosis of RML bronchus in one [7], 
while the other had a UIP pattern with multifocal 
narrowing of left upper lobe bronchus [14]. In our 
study, multifocal bronchial stenosis and peribron-
chial cuffing were exclusively observed in patients 
with BAF. Multifocal bronchial stenosis, when pre-
sent, can be considered as a feature characteristic 
of BAF [4, 10].
Functional status assessment revealed that 
walk distance in patients with BAF was signifi-
cantly lower as compared to those with anthra-
cosis only. In addition, on 6MWT more than half 
the BAF patients (58.3%) desaturated with a fall 
in SpO2 ≥ 4% from the baseline which was consi-
dered significant [11]. On functional assessment, 
patients with BAF fared poorer than those with 
anthracosis, a finding which is yet to be docu-
mented in the literature. Although, obstruction 
is most commonly observed on PFT in patients 
with BAF [16, 18] a non-obstructive (suggestive 
of restriction/mixed defect) or even a normal 
pattern can be encountered. In our study too, 
obstructive, non-obstructive and normal patterns 
were observed with normal spirometry being the 
most frequent finding followed by non-obstruc-
tive and obstructive defects. In all three groups, 
most of the patients had an abnormal spirometric 
finding (obstructive or non-obstructive defect). 
This could be explained from the fact that all 
the three groups had long standing exposure to 
biomass fuel smoke. 
Biomass fuel smoke exposure can lead to both 
an obstructive as well as a restrictive ventilato-
ry defect. This was reflected in the spirometric 
findings in our patients where the most common 
ventilatory defect was a non-obstructive pattern 
(suggestive of restriction/mixed defect). Biomass 
fuel smoke exposure probably leads to activation 
Advances in Respiratory Medicine 2017, vol. 85, no. 3, pages 127–135 
134 www.journals.viamedica.pl
of pulmonary fibroblasts and an increased pro-
duction of fibronectin [19]. This could possibly 
explain the non-obstructive pattern (suggestive 
of restriction/mixed defect) on spirometry as a re-
sult of increased fibrosis. In addition, a normal 
spirometric finding can be seen in patients with 
biomass fuel smoke exposure. In a study from 
Korea in patients with BAF, half of them had a nor-
mal spirometric finding [20]. Similarly, a normal 
spirometry was the most common finding in our 
patients with BAF as well as anthracosis. Further-
more, in Group 1, it was observed that there was 
a significant inverse correlation between expo-
sure index, 6MWD and spirometric parameters. 
Patients with BAF had a greater degree of biomass 
fuel smoke exposure, covered lesser distance on 
six-minute walk test. 
BAF, as visualised on FOB, affects the mucosa 
around branching points of the bronchus [16] and 
commonly involves RML as also both upper lobes. 
In 54 patients from Korea [15], RML was affected 
in 34 (63%) subjects. Subsequently, another large 
Korean study [16] confirmed that RML was most 
frequently damaged (229/333 [68.8%]). We too 
noted that RML bronchus was mostly affected 
followed by both upper lobe bronchi. In a report 
of 30 patients with anthracosis alone, pigmen-
tation was frequently observed in both upper 
lobes and RML bronchi [21]. In our patients with 
anthracosis alone, pigmentation was largely seen 
in the RML and the LUL bronchi followed by RUL 
and LLL lobe bronchi. 
Tuberculosis was most commonly associated 
disease in our entire study population documen-
ted in 4/60 patients (6.6%) followed by malignan-
cy (5%). In patients with BAF, active tuberculosis 
was associated in 3/24 (12.5%) patients while 
a history of antituberculous therapy in the past 
was reported in 6/24 (25%) patients. Malignancy 
and pneumonia were associated in 2/24 (8.3%) 
patients each. Gupta and Shah [10] in their review 
of 907 patients with BAF observed that incidence 
of tuberculosis, pneumonia and malignancy were 
31.4%, 30% and 4.8% respectively. 
The small sample size was the major limi-
tation in our study as many patients refused to 
undergo an invasive procedure like FOB. Further-
more, all our patients were females as males who 
had exposure to biomass fuel smoke were also 
smokers and had to be excluded. 
Conclusion
Not surprisingly, all our patients were fema-
les with significant biomass fuel smoke exposure. 
In comparison to those with anthracosis, patients 
with BAF had poor functional status. Multifocal 
bronchial stenosis and peribronchial soft tissue 
cuffing were specific imaging signs for BAF. Since 
exposure to biomass fuel smoke is a risk factor 
inherent to COPD and BAF, most patients are 
often labelled as COPD without undergoing fur-
ther workup to exclude BAF [4, 10]. Nearly two 
decades have passed since this clinical entity was 
highlighted but it is yet to be ascertained as to 
why some subjects exposed to biomass fuel smoke 
develop BAF while others develop anthracosis or 
even remain unaffected by both these entities. 
Though our patients with BAF had a significantly 
greater degree of biomass fuel smoke exposure 
and significantly poorer functional status than 
those with anthracosis, it would be intriguing to 
speculate whether BAF or anthracosis are two 
different stages of the same disease process or two 
separate clinical phenomenon. The pathophy-
siology and clinical implications of this disease 
process still needs to be elucidated. Since FOB 
continues to remain the only diagnostic modality 
confirmatory of BAF/anthracosis, it is imperative 
not only to develop non-invasive modalities for an 
early diagnosis but also to formulate preventive 
and management strategies for this clinical entity. 
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